Optimized disease diagnosis using protein-based nanomaterials

Purpose and goal:

The goal of the project was to explore the conditions for introducing BTM’s innovative technology for highly sensitive diagnostics on the Swedish market and, if possible, to launch co-operations allowing for such introduction. The goal was achieved through a range of market analyses and through establishing a co-operation with a suitable partner. The co-operation continues and is going to lead to an integration of BTM’s technology in the partner’s offering to the customers.

Expected results and effects:

Conditions on the Swedish diagnostic market have been mapped and a co-operation with a partner company has been established. This will allow for the protein-based nanofibril technology’s integration I marketable products and development of new products. In extension, it is expected to considerably increase access to cost-effective highly sensitive diagnostics and by that, to early diagnoses and more cost-effective treatments with better results for the patients.

Approach and implementation:

The project was conducted by a diligent examination of the market and the actors active within it. The results of this work become a ground for the board’s decisions on the company’s strategic direction. They were also a basis for identification of potential co-operation partners, which one of the investigated firms has already become.

Thus, some of the time and resources could be saved and redirected to enhancing BTM’s position on the market by expanding the patent protection of the technology.